Comparison of the efficacy of brolucizumab with natural disease progression in wet AMD using clinical data from the Phase III HAWK and HARRIER trials and modelled placebo data

2020 
Aim: To compare the treatment effect of brolucizumab, a novel anti-vascular endothelial growth factor therapeutic, with a putative placebo in patients with wet age-related macular degeneration.Mate...
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    16
    References
    2
    Citations
    NaN
    KQI
    []